The Medicines Intelligence Data Platform: A Population‐Based Data Resource From New South Wales, Australia
ABSTRACT Background The Medicines Intelligence (MedIntel) Data Platform is an anonymised linked data resource designed to generate real‐world evidence on prescribed medicine use, effectiveness, safety, costs and cost‐effectiveness in Australia. Results The platform comprises Medicare‐eligible people...
Gespeichert in:
| Veröffentlicht in: | Pharmacoepidemiology and drug safety 2024-08, Vol.33 (8), p.e5887-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 8 |
| container_start_page | e5887 |
| container_title | Pharmacoepidemiology and drug safety |
| container_volume | 33 |
| creator | Zoega, Helga Falster, Michael O. Gillies, Malcolm B. Litchfield, Melisa Camacho, Ximena Bruno, Claudia Daniels, Benjamin Donnolley, Natasha Havard, Alys Schaffer, Andrea L. Chambers, Georgina Degenhardt, Louisa Dobbins, Timothy Gisev, Natasa Ivers, Rebecca Jorm, Louisa Liu, Bette Vajdic, Claire M. Pearson, Sallie‐Anne |
| description | ABSTRACT
Background
The Medicines Intelligence (MedIntel) Data Platform is an anonymised linked data resource designed to generate real‐world evidence on prescribed medicine use, effectiveness, safety, costs and cost‐effectiveness in Australia.
Results
The platform comprises Medicare‐eligible people who are ≥18 years and residing in New South Wales (NSW), Australia, any time during 2005–2020, with linked administrative data on dispensed prescription medicines (Pharmaceutical Benefits Scheme), health service use (Medicare Benefits Schedule), emergency department visits (NSW Emergency Department Data Collection), hospitalisations (NSW Admitted Patient Data Collection) plus death (National Death Index) and cancer registrations (NSW Cancer Registry). Data are currently available to 2022, with approval to update the cohort and data collections annually. The platform includes 7.4 million unique people across all years, covering 36.9% of the Australian adult population; the overall population increased from 4.8 M in 2005 to 6.0 M in 2020. As of 1 January 2019 (the last pre‐pandemic year), the cohort had a mean age of 48.7 years (51.1% female), with most people (4.4 M, 74.7%) residing in a major city. In 2019, 4.4 M people (73.3%) were dispensed a medicine, 1.2 M (20.5%) were hospitalised, 5.3 M (89.4%) had a GP or specialist appointment, and 54 003 people died. Anti‐infectives were the most prevalent medicines dispensed to the cohort in 2019 (43.1%), followed by nervous system (32.2%) and cardiovascular system medicines (30.2%).
Conclusion
The MedIntel Data Platform creates opportunities for national and international research collaborations and enables us to address contemporary clinically‐ and policy‐relevant research questions about quality use of medicines and health outcomes in Australia and globally. |
| doi_str_mv | 10.1002/pds.5887 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3093174344</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3093174344</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2747-43c7f97a4fce24c867d5fef9f306107d39ce88a5bd5368ef967f49196df2194b3</originalsourceid><addsrcrecordid>eNp1kctKxDAUhoMo3sEnkIAbF3ZMJknTuBsvo4KXwQsuSyY90UrbjEmLuPMRfEafxIzjBQRXSThfPs45P0IblPQoIf3dSRF6IsvkHFqmRKmECiHnp3fBkkykagmthPBISKwpvoiWmKJccMKXUXXzAPgcitKUDQR82rRQVeU9NAbwoW41HlW6tc7Xe3iAR27SxWfpmvfXt30doJgxVxBc5-OPoXc1voBnfO269gHf6QrCDh50ofW6KvUaWrC6CrD-da6i2-HRzcFJcnZ5fHowOEtMX3KZcGakVVJza6DPTZbKQliwyjKSUiILpgxkmRbjQrA0i4VUWq6oSgvbp4qP2Srannkn3j11ENq8LoOJg-kGXBdyRhSjkjPOI7r1B32MozSxuynFRZoxKn6FxrsQPNh84sta-5ecknyaQB4TyKcJRHTzS9iNayh-wO-VRyCZAc9lBS__ivLR4fWn8AMn3Y8y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3094568315</pqid></control><display><type>article</type><title>The Medicines Intelligence Data Platform: A Population‐Based Data Resource From New South Wales, Australia</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Zoega, Helga ; Falster, Michael O. ; Gillies, Malcolm B. ; Litchfield, Melisa ; Camacho, Ximena ; Bruno, Claudia ; Daniels, Benjamin ; Donnolley, Natasha ; Havard, Alys ; Schaffer, Andrea L. ; Chambers, Georgina ; Degenhardt, Louisa ; Dobbins, Timothy ; Gisev, Natasa ; Ivers, Rebecca ; Jorm, Louisa ; Liu, Bette ; Vajdic, Claire M. ; Pearson, Sallie‐Anne</creator><creatorcontrib>Zoega, Helga ; Falster, Michael O. ; Gillies, Malcolm B. ; Litchfield, Melisa ; Camacho, Ximena ; Bruno, Claudia ; Daniels, Benjamin ; Donnolley, Natasha ; Havard, Alys ; Schaffer, Andrea L. ; Chambers, Georgina ; Degenhardt, Louisa ; Dobbins, Timothy ; Gisev, Natasa ; Ivers, Rebecca ; Jorm, Louisa ; Liu, Bette ; Vajdic, Claire M. ; Pearson, Sallie‐Anne</creatorcontrib><description>ABSTRACT
Background
The Medicines Intelligence (MedIntel) Data Platform is an anonymised linked data resource designed to generate real‐world evidence on prescribed medicine use, effectiveness, safety, costs and cost‐effectiveness in Australia.
Results
The platform comprises Medicare‐eligible people who are ≥18 years and residing in New South Wales (NSW), Australia, any time during 2005–2020, with linked administrative data on dispensed prescription medicines (Pharmaceutical Benefits Scheme), health service use (Medicare Benefits Schedule), emergency department visits (NSW Emergency Department Data Collection), hospitalisations (NSW Admitted Patient Data Collection) plus death (National Death Index) and cancer registrations (NSW Cancer Registry). Data are currently available to 2022, with approval to update the cohort and data collections annually. The platform includes 7.4 million unique people across all years, covering 36.9% of the Australian adult population; the overall population increased from 4.8 M in 2005 to 6.0 M in 2020. As of 1 January 2019 (the last pre‐pandemic year), the cohort had a mean age of 48.7 years (51.1% female), with most people (4.4 M, 74.7%) residing in a major city. In 2019, 4.4 M people (73.3%) were dispensed a medicine, 1.2 M (20.5%) were hospitalised, 5.3 M (89.4%) had a GP or specialist appointment, and 54 003 people died. Anti‐infectives were the most prevalent medicines dispensed to the cohort in 2019 (43.1%), followed by nervous system (32.2%) and cardiovascular system medicines (30.2%).
Conclusion
The MedIntel Data Platform creates opportunities for national and international research collaborations and enables us to address contemporary clinically‐ and policy‐relevant research questions about quality use of medicines and health outcomes in Australia and globally.</description><identifier>ISSN: 1053-8569</identifier><identifier>ISSN: 1099-1557</identifier><identifier>EISSN: 1099-1557</identifier><identifier>DOI: 10.1002/pds.5887</identifier><identifier>PMID: 39145404</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Inc</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Australia ; Cardiovascular system ; Cost-Benefit Analysis ; Data collection ; data linkage ; Databases, Factual ; Emergency medical care ; Female ; Hospitalization - statistics & numerical data ; Humans ; Intelligence ; Male ; Medicare ; Middle Aged ; Nervous system ; New South Wales - epidemiology ; pharmacoepidemiology ; Pharmacoepidemiology - methods ; population‐based ; Prescription Drugs - economics ; Prescription Drugs - therapeutic use ; real‐world data ; Young Adult</subject><ispartof>Pharmacoepidemiology and drug safety, 2024-08, Vol.33 (8), p.e5887-n/a</ispartof><rights>2024 The Author(s). published by John Wiley & Sons Ltd.</rights><rights>2024 The Author(s). Pharmacoepidemiology and Drug Safety published by John Wiley & Sons Ltd.</rights><rights>2024. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2747-43c7f97a4fce24c867d5fef9f306107d39ce88a5bd5368ef967f49196df2194b3</cites><orcidid>0000-0003-0452-8470 ; 0000-0003-0215-3249 ; 0000-0003-0761-9028 ; 0000-0002-3612-8298 ; 0000-0001-9038-8050 ; 0000-0001-7137-6855 ; 0000-0003-0390-661X ; 0000-0001-6444-7272 ; 0000-0002-0787-5825 ; 0000-0001-7789-3415 ; 0000-0002-3701-4997 ; 0000-0003-3409-4386 ; 0000-0003-0002-7724 ; 0000-0002-2371-1441 ; 0000-0001-6563-8804 ; 0000-0003-1841-9056 ; 0000-0002-8513-2218 ; 0000-0003-3448-662X ; 0000-0001-8617-6055</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpds.5887$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpds.5887$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39145404$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zoega, Helga</creatorcontrib><creatorcontrib>Falster, Michael O.</creatorcontrib><creatorcontrib>Gillies, Malcolm B.</creatorcontrib><creatorcontrib>Litchfield, Melisa</creatorcontrib><creatorcontrib>Camacho, Ximena</creatorcontrib><creatorcontrib>Bruno, Claudia</creatorcontrib><creatorcontrib>Daniels, Benjamin</creatorcontrib><creatorcontrib>Donnolley, Natasha</creatorcontrib><creatorcontrib>Havard, Alys</creatorcontrib><creatorcontrib>Schaffer, Andrea L.</creatorcontrib><creatorcontrib>Chambers, Georgina</creatorcontrib><creatorcontrib>Degenhardt, Louisa</creatorcontrib><creatorcontrib>Dobbins, Timothy</creatorcontrib><creatorcontrib>Gisev, Natasa</creatorcontrib><creatorcontrib>Ivers, Rebecca</creatorcontrib><creatorcontrib>Jorm, Louisa</creatorcontrib><creatorcontrib>Liu, Bette</creatorcontrib><creatorcontrib>Vajdic, Claire M.</creatorcontrib><creatorcontrib>Pearson, Sallie‐Anne</creatorcontrib><title>The Medicines Intelligence Data Platform: A Population‐Based Data Resource From New South Wales, Australia</title><title>Pharmacoepidemiology and drug safety</title><addtitle>Pharmacoepidemiol Drug Saf</addtitle><description>ABSTRACT
Background
The Medicines Intelligence (MedIntel) Data Platform is an anonymised linked data resource designed to generate real‐world evidence on prescribed medicine use, effectiveness, safety, costs and cost‐effectiveness in Australia.
Results
The platform comprises Medicare‐eligible people who are ≥18 years and residing in New South Wales (NSW), Australia, any time during 2005–2020, with linked administrative data on dispensed prescription medicines (Pharmaceutical Benefits Scheme), health service use (Medicare Benefits Schedule), emergency department visits (NSW Emergency Department Data Collection), hospitalisations (NSW Admitted Patient Data Collection) plus death (National Death Index) and cancer registrations (NSW Cancer Registry). Data are currently available to 2022, with approval to update the cohort and data collections annually. The platform includes 7.4 million unique people across all years, covering 36.9% of the Australian adult population; the overall population increased from 4.8 M in 2005 to 6.0 M in 2020. As of 1 January 2019 (the last pre‐pandemic year), the cohort had a mean age of 48.7 years (51.1% female), with most people (4.4 M, 74.7%) residing in a major city. In 2019, 4.4 M people (73.3%) were dispensed a medicine, 1.2 M (20.5%) were hospitalised, 5.3 M (89.4%) had a GP or specialist appointment, and 54 003 people died. Anti‐infectives were the most prevalent medicines dispensed to the cohort in 2019 (43.1%), followed by nervous system (32.2%) and cardiovascular system medicines (30.2%).
Conclusion
The MedIntel Data Platform creates opportunities for national and international research collaborations and enables us to address contemporary clinically‐ and policy‐relevant research questions about quality use of medicines and health outcomes in Australia and globally.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Australia</subject><subject>Cardiovascular system</subject><subject>Cost-Benefit Analysis</subject><subject>Data collection</subject><subject>data linkage</subject><subject>Databases, Factual</subject><subject>Emergency medical care</subject><subject>Female</subject><subject>Hospitalization - statistics & numerical data</subject><subject>Humans</subject><subject>Intelligence</subject><subject>Male</subject><subject>Medicare</subject><subject>Middle Aged</subject><subject>Nervous system</subject><subject>New South Wales - epidemiology</subject><subject>pharmacoepidemiology</subject><subject>Pharmacoepidemiology - methods</subject><subject>population‐based</subject><subject>Prescription Drugs - economics</subject><subject>Prescription Drugs - therapeutic use</subject><subject>real‐world data</subject><subject>Young Adult</subject><issn>1053-8569</issn><issn>1099-1557</issn><issn>1099-1557</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp1kctKxDAUhoMo3sEnkIAbF3ZMJknTuBsvo4KXwQsuSyY90UrbjEmLuPMRfEafxIzjBQRXSThfPs45P0IblPQoIf3dSRF6IsvkHFqmRKmECiHnp3fBkkykagmthPBISKwpvoiWmKJccMKXUXXzAPgcitKUDQR82rRQVeU9NAbwoW41HlW6tc7Xe3iAR27SxWfpmvfXt30doJgxVxBc5-OPoXc1voBnfO269gHf6QrCDh50ofW6KvUaWrC6CrD-da6i2-HRzcFJcnZ5fHowOEtMX3KZcGakVVJza6DPTZbKQliwyjKSUiILpgxkmRbjQrA0i4VUWq6oSgvbp4qP2Srannkn3j11ENq8LoOJg-kGXBdyRhSjkjPOI7r1B32MozSxuynFRZoxKn6FxrsQPNh84sta-5ecknyaQB4TyKcJRHTzS9iNayh-wO-VRyCZAc9lBS__ivLR4fWn8AMn3Y8y</recordid><startdate>202408</startdate><enddate>202408</enddate><creator>Zoega, Helga</creator><creator>Falster, Michael O.</creator><creator>Gillies, Malcolm B.</creator><creator>Litchfield, Melisa</creator><creator>Camacho, Ximena</creator><creator>Bruno, Claudia</creator><creator>Daniels, Benjamin</creator><creator>Donnolley, Natasha</creator><creator>Havard, Alys</creator><creator>Schaffer, Andrea L.</creator><creator>Chambers, Georgina</creator><creator>Degenhardt, Louisa</creator><creator>Dobbins, Timothy</creator><creator>Gisev, Natasa</creator><creator>Ivers, Rebecca</creator><creator>Jorm, Louisa</creator><creator>Liu, Bette</creator><creator>Vajdic, Claire M.</creator><creator>Pearson, Sallie‐Anne</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0452-8470</orcidid><orcidid>https://orcid.org/0000-0003-0215-3249</orcidid><orcidid>https://orcid.org/0000-0003-0761-9028</orcidid><orcidid>https://orcid.org/0000-0002-3612-8298</orcidid><orcidid>https://orcid.org/0000-0001-9038-8050</orcidid><orcidid>https://orcid.org/0000-0001-7137-6855</orcidid><orcidid>https://orcid.org/0000-0003-0390-661X</orcidid><orcidid>https://orcid.org/0000-0001-6444-7272</orcidid><orcidid>https://orcid.org/0000-0002-0787-5825</orcidid><orcidid>https://orcid.org/0000-0001-7789-3415</orcidid><orcidid>https://orcid.org/0000-0002-3701-4997</orcidid><orcidid>https://orcid.org/0000-0003-3409-4386</orcidid><orcidid>https://orcid.org/0000-0003-0002-7724</orcidid><orcidid>https://orcid.org/0000-0002-2371-1441</orcidid><orcidid>https://orcid.org/0000-0001-6563-8804</orcidid><orcidid>https://orcid.org/0000-0003-1841-9056</orcidid><orcidid>https://orcid.org/0000-0002-8513-2218</orcidid><orcidid>https://orcid.org/0000-0003-3448-662X</orcidid><orcidid>https://orcid.org/0000-0001-8617-6055</orcidid></search><sort><creationdate>202408</creationdate><title>The Medicines Intelligence Data Platform: A Population‐Based Data Resource From New South Wales, Australia</title><author>Zoega, Helga ; Falster, Michael O. ; Gillies, Malcolm B. ; Litchfield, Melisa ; Camacho, Ximena ; Bruno, Claudia ; Daniels, Benjamin ; Donnolley, Natasha ; Havard, Alys ; Schaffer, Andrea L. ; Chambers, Georgina ; Degenhardt, Louisa ; Dobbins, Timothy ; Gisev, Natasa ; Ivers, Rebecca ; Jorm, Louisa ; Liu, Bette ; Vajdic, Claire M. ; Pearson, Sallie‐Anne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2747-43c7f97a4fce24c867d5fef9f306107d39ce88a5bd5368ef967f49196df2194b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Australia</topic><topic>Cardiovascular system</topic><topic>Cost-Benefit Analysis</topic><topic>Data collection</topic><topic>data linkage</topic><topic>Databases, Factual</topic><topic>Emergency medical care</topic><topic>Female</topic><topic>Hospitalization - statistics & numerical data</topic><topic>Humans</topic><topic>Intelligence</topic><topic>Male</topic><topic>Medicare</topic><topic>Middle Aged</topic><topic>Nervous system</topic><topic>New South Wales - epidemiology</topic><topic>pharmacoepidemiology</topic><topic>Pharmacoepidemiology - methods</topic><topic>population‐based</topic><topic>Prescription Drugs - economics</topic><topic>Prescription Drugs - therapeutic use</topic><topic>real‐world data</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zoega, Helga</creatorcontrib><creatorcontrib>Falster, Michael O.</creatorcontrib><creatorcontrib>Gillies, Malcolm B.</creatorcontrib><creatorcontrib>Litchfield, Melisa</creatorcontrib><creatorcontrib>Camacho, Ximena</creatorcontrib><creatorcontrib>Bruno, Claudia</creatorcontrib><creatorcontrib>Daniels, Benjamin</creatorcontrib><creatorcontrib>Donnolley, Natasha</creatorcontrib><creatorcontrib>Havard, Alys</creatorcontrib><creatorcontrib>Schaffer, Andrea L.</creatorcontrib><creatorcontrib>Chambers, Georgina</creatorcontrib><creatorcontrib>Degenhardt, Louisa</creatorcontrib><creatorcontrib>Dobbins, Timothy</creatorcontrib><creatorcontrib>Gisev, Natasa</creatorcontrib><creatorcontrib>Ivers, Rebecca</creatorcontrib><creatorcontrib>Jorm, Louisa</creatorcontrib><creatorcontrib>Liu, Bette</creatorcontrib><creatorcontrib>Vajdic, Claire M.</creatorcontrib><creatorcontrib>Pearson, Sallie‐Anne</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacoepidemiology and drug safety</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zoega, Helga</au><au>Falster, Michael O.</au><au>Gillies, Malcolm B.</au><au>Litchfield, Melisa</au><au>Camacho, Ximena</au><au>Bruno, Claudia</au><au>Daniels, Benjamin</au><au>Donnolley, Natasha</au><au>Havard, Alys</au><au>Schaffer, Andrea L.</au><au>Chambers, Georgina</au><au>Degenhardt, Louisa</au><au>Dobbins, Timothy</au><au>Gisev, Natasa</au><au>Ivers, Rebecca</au><au>Jorm, Louisa</au><au>Liu, Bette</au><au>Vajdic, Claire M.</au><au>Pearson, Sallie‐Anne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Medicines Intelligence Data Platform: A Population‐Based Data Resource From New South Wales, Australia</atitle><jtitle>Pharmacoepidemiology and drug safety</jtitle><addtitle>Pharmacoepidemiol Drug Saf</addtitle><date>2024-08</date><risdate>2024</risdate><volume>33</volume><issue>8</issue><spage>e5887</spage><epage>n/a</epage><pages>e5887-n/a</pages><issn>1053-8569</issn><issn>1099-1557</issn><eissn>1099-1557</eissn><abstract>ABSTRACT
Background
The Medicines Intelligence (MedIntel) Data Platform is an anonymised linked data resource designed to generate real‐world evidence on prescribed medicine use, effectiveness, safety, costs and cost‐effectiveness in Australia.
Results
The platform comprises Medicare‐eligible people who are ≥18 years and residing in New South Wales (NSW), Australia, any time during 2005–2020, with linked administrative data on dispensed prescription medicines (Pharmaceutical Benefits Scheme), health service use (Medicare Benefits Schedule), emergency department visits (NSW Emergency Department Data Collection), hospitalisations (NSW Admitted Patient Data Collection) plus death (National Death Index) and cancer registrations (NSW Cancer Registry). Data are currently available to 2022, with approval to update the cohort and data collections annually. The platform includes 7.4 million unique people across all years, covering 36.9% of the Australian adult population; the overall population increased from 4.8 M in 2005 to 6.0 M in 2020. As of 1 January 2019 (the last pre‐pandemic year), the cohort had a mean age of 48.7 years (51.1% female), with most people (4.4 M, 74.7%) residing in a major city. In 2019, 4.4 M people (73.3%) were dispensed a medicine, 1.2 M (20.5%) were hospitalised, 5.3 M (89.4%) had a GP or specialist appointment, and 54 003 people died. Anti‐infectives were the most prevalent medicines dispensed to the cohort in 2019 (43.1%), followed by nervous system (32.2%) and cardiovascular system medicines (30.2%).
Conclusion
The MedIntel Data Platform creates opportunities for national and international research collaborations and enables us to address contemporary clinically‐ and policy‐relevant research questions about quality use of medicines and health outcomes in Australia and globally.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Inc</pub><pmid>39145404</pmid><doi>10.1002/pds.5887</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0003-0452-8470</orcidid><orcidid>https://orcid.org/0000-0003-0215-3249</orcidid><orcidid>https://orcid.org/0000-0003-0761-9028</orcidid><orcidid>https://orcid.org/0000-0002-3612-8298</orcidid><orcidid>https://orcid.org/0000-0001-9038-8050</orcidid><orcidid>https://orcid.org/0000-0001-7137-6855</orcidid><orcidid>https://orcid.org/0000-0003-0390-661X</orcidid><orcidid>https://orcid.org/0000-0001-6444-7272</orcidid><orcidid>https://orcid.org/0000-0002-0787-5825</orcidid><orcidid>https://orcid.org/0000-0001-7789-3415</orcidid><orcidid>https://orcid.org/0000-0002-3701-4997</orcidid><orcidid>https://orcid.org/0000-0003-3409-4386</orcidid><orcidid>https://orcid.org/0000-0003-0002-7724</orcidid><orcidid>https://orcid.org/0000-0002-2371-1441</orcidid><orcidid>https://orcid.org/0000-0001-6563-8804</orcidid><orcidid>https://orcid.org/0000-0003-1841-9056</orcidid><orcidid>https://orcid.org/0000-0002-8513-2218</orcidid><orcidid>https://orcid.org/0000-0003-3448-662X</orcidid><orcidid>https://orcid.org/0000-0001-8617-6055</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1053-8569 |
| ispartof | Pharmacoepidemiology and drug safety, 2024-08, Vol.33 (8), p.e5887-n/a |
| issn | 1053-8569 1099-1557 1099-1557 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3093174344 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adolescent Adult Aged Aged, 80 and over Australia Cardiovascular system Cost-Benefit Analysis Data collection data linkage Databases, Factual Emergency medical care Female Hospitalization - statistics & numerical data Humans Intelligence Male Medicare Middle Aged Nervous system New South Wales - epidemiology pharmacoepidemiology Pharmacoepidemiology - methods population‐based Prescription Drugs - economics Prescription Drugs - therapeutic use real‐world data Young Adult |
| title | The Medicines Intelligence Data Platform: A Population‐Based Data Resource From New South Wales, Australia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T22%3A16%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Medicines%20Intelligence%20Data%20Platform:%20A%20Population%E2%80%90Based%20Data%20Resource%20From%20New%20South%20Wales,%20Australia&rft.jtitle=Pharmacoepidemiology%20and%20drug%20safety&rft.au=Zoega,%20Helga&rft.date=2024-08&rft.volume=33&rft.issue=8&rft.spage=e5887&rft.epage=n/a&rft.pages=e5887-n/a&rft.issn=1053-8569&rft.eissn=1099-1557&rft_id=info:doi/10.1002/pds.5887&rft_dat=%3Cproquest_cross%3E3093174344%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3094568315&rft_id=info:pmid/39145404&rfr_iscdi=true |